Compared to other tumor targets that are vastly used in nuclear medicine such as prostate-specific membrane antigen (PSMA) or somatostatin receptor (SSTR), radiopharmaceuticals targeting FAP do not address the cancer cells directly but indirectly via its TME. This evidence concerns the gene FAP and neoplasm.